Hub : Traits :

Father's age at death

17 significantly associated models · 9 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	12	111154626	112582540	1	1	3.0e-08	1.1e-05	0.28	94	SH2B3
2	15	40085637	41752852	3	1	2.6e-08	1.2e-07	0.26	95	GCHFR
3	15	78032707	79573404	4	1	1.0e-11	7.9e-12	1.00	100	PSMA4
4	15	90730363	92135418	1	1	1.2e-07	5.0e-07	0.54	98	FES

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Pack years adult smoking proportion	56.76	2	1	2.2	0.00	1.00	GCHFR PSMA4
Pack years of smoking	52.09	2	1	2.2	0.00	1.00	GCHFR PSMA4
Blood Eosinophil Count	45.01	1	1	2.2	0.00	1.00	SH2B3
Hypothyroidism (self reported)	29.53	2	1	2.2	0.00	1.00	GCHFR SH2B3
Systolic Blood Pressure	26.78	3	2	4.4	0.00	1.00	FES GCHFR SH2B3
Vascular/heart problems diagnosed by doctor	26.36	2	2	4.4	0.00	1.00	FES SH2B3
Diastolic blood pressure, automated reading	24.79	2	2	4.4	0.00	1.00	FES SH2B3
Hypothyroidism/myxoedema (self-reported)	23.99	1	1	2.2	0.00	1.00	SH2B3
High blood pressure	23.77	2	2	4.4	0.00	1.00	FES SH2B3
Medication: Levothyroxine sodium	23.74	1	1	2.2	0.00	1.00	SH2B3
Hypertension (Self-reported)	23.41	2	2	4.4	0.00	1.00	FES SH2B3
Blood White Count	20.99	2	2	4.4	0.00	1.00	FES SH2B3
Systolic blood pressure, automated reading	20.80	2	2	4.4	0.00	1.00	FES SH2B3
Medication: Blood pressure	20.29	2	2	4.4	0.00	1.00	FES SH2B3
Cardiovascular Disease	20.08	2	2	4.4	0.00	1.00	FES SH2B3
High blood pressure (mother)	19.06	2	1	2.2	0.00	1.00	FES SH2B3
Medication: Blood pressure	18.58	2	2	4.4	0.00	1.00	FES SH2B3
Medication for cholesterol, blood pressure or diabetes	17.01	2	2	4.4	0.00	1.00	FES SH2B3
Medication: Atenolol	16.59	2	2	4.4	0.00	1.00	FES SH2B3
Birth weight of first child	16.12	2	2	4.4	0.00	1.00	FES SH2B3
Lung cancer (father)	15.80	2	1	2.2	0.00	1.00	FES PSMA4
Illnesses of father: High blood pressure	14.71	2	1	2.2	0.00	1.00	FES SH2B3
Illnesses of father: Heart disease	13.60	2	1	2.2	0.00	1.00	FES SH2B3
Illnesses of father: None of the above (group 1)	13.43	2	1	2.2	0.00	1.00	FES SH2B3
Angina (self-reported)	13.13	2	1	2.2	0.00	1.00	FES PSMA4
Angina	12.98	2	1	2.2	0.00	1.00	FES PSMA4
Chronic bronchitis/emphysema (father)	12.57	1	1	2.2	0.00	1.00	PSMA4
Illnesses of mother	12.29	2	1	2.2	0.00	1.00	FES SH2B3
High blood pressure (siblings)	12.12	3	1	2.2	0.00	1.00	FES GCHFR SH2B3
Illnesses of siblings	11.53	3	1	2.2	0.00	1.00	FES GCHFR SH2B3
Chronic bronchitis/emphysema (mother)	10.67	1	1	2.2	0.00	1.00	PSMA4
Heart attack/myocardial infarction (self-reported)	10.05	2	1	2.2	0.00	1.00	FES SH2B3
Schizophrenia (2018)	9.95	2	1	2.2	0.00	1.00	FES PSMA4
Risk taking	9.65	3	0	0.0	0.00	1.00	FES GCHFR PSMA4
Heart attack	9.53	2	1	2.2	0.00	1.00	FES SH2B3
Medication: Aspirin	9.45	2	1	2.2	0.00	1.00	FES SH2B3
Bipolar Disorder or Schizophrenia	9.44	2	1	2.2	0.00	1.00	FES PSMA4
Medication: Aspirin	9.28	2	1	2.2	0.00	1.00	FES SH2B3
Ever smoked	9.20	4	0	0.0	0.41	0.59	FES GCHFR PSMA4 SH2B3
Birth weight	9.19	2	2	4.4	0.00	1.00	FES SH2B3
Mean time to correctly identify matches	9.17	2	1	2.2	0.00	1.00	FES SH2B3
Medication for cholesterol	9.07	2	1	2.2	0.00	1.00	FES SH2B3
Smoking status: Previous	8.55	2	0	0.0	0.00	1.00	PSMA4 SH2B3
Reaction Time	8.52	1	1	2.2	0.00	1.00	SH2B3
Forced expiratory volume in 1-second (FEV1), predicted percentage	8.50	1	1	2.2	0.00	1.00	PSMA4
Number of treatments/medications taken	8.46	2	1	2.2	0.00	1.00	FES SH2B3
Schizophrenia (2014)	8.41	2	1	2.2	0.00	1.00	FES PSMA4
Medication: Bendroflumethiazide	8.37	2	1	2.2	0.00	1.00	FES SH2B3
Taking other prescription medications	8.16	2	1	2.2	0.00	1.00	GCHFR SH2B3
Medication: Cholesterol lowering	8.13	2	1	2.2	0.00	1.00	FES SH2B3
Medication: Amlodipine	8.00	1	1	2.2	0.00	1.00	FES
Past tobacco smoking	7.28	3	0	0.0	0.00	1.00	FES GCHFR SH2B3
Blood Red Count	7.22	3	1	2.2	0.00	1.00	FES PSMA4 SH2B3
Medication: Ramipril	7.18	2	0	0.0	0.00	1.00	FES SH2B3
Number of self-reported non-cancer illnesses	7.01	1	1	2.2	0.00	1.00	SH2B3
Heart disease (siblings)	6.93	1	0	0.0	0.00	1.00	FES
Medication: Simvastatin	6.75	1	1	2.2	0.00	1.00	FES
Blood Platelet Count	6.53	1	1	2.2	0.00	1.00	SH2B3
Mother's age at death	6.46	2	0	0.0	0.00	1.00	PSMA4 SH2B3
Pain experienced in last month	5.85	2	0	0.0	0.00	1.00	PSMA4 SH2B3
Prostate Cancer	5.73	1	0	0.0	0.00	1.00	GCHFR
Heart disease (mother)	5.65	1	0	0.0	0.00	1.00	FES
Primary Biliary Cirrhosis	5.55	1	1	2.2	0.00	1.00	SH2B3
Medication: Lisinopril	5.42	2	0	0.0	0.00	1.00	FES SH2B3
Fed-up feelings	5.17	1	1	2.2	0.00	1.00	SH2B3
Breast Cancer	5.09	2	0	0.0	0.00	1.00	FES GCHFR
Pulse wave peak to peak time	5.05	2	0	0.0	0.00	1.00	FES SH2B3
Smoking Status	4.95	2	0	0.0	0.00	1.00	FES GCHFR
Pulse wave Arterial Stiffness index	4.86	2	0	0.0	0.00	1.00	FES SH2B3
Coronary Artery Disease (CAD)	4.85	1	0	0.0	0.00	1.00	SH2B3
Exposure to tobacco smoke outside home	4.74	2	0	0.0	0.00	1.00	GCHFR SH2B3
Number of live births	4.61	2	0	0.0	0.00	1.00	FES GCHFR
LDL Cholesterol	4.57	1	0	0.0	0.00	1.00	SH2B3
Allergy or Eczema	4.57	3	0	0.0	0.00	1.00	FES PSMA4 SH2B3
Long-standing illness, disability or infirmity	4.52	2	0	0.0	0.00	1.00	GCHFR SH2B3
Rheumatoid Arthritis	4.41	1	0	0.0	0.00	1.00	SH2B3
Loneliness, isolation	4.38	1	0	0.0	0.00	1.00	SH2B3
Allergy	4.29	2	0	0.0	0.00	1.00	FES GCHFR
Number of incorrect matches in round	4.22	1	0	0.0	0.00	1.00	FES
Sensitivity / hurt feelings	4.14	1	1	2.2	0.00	1.00	FES
Current tobacco smoking	4.12	1	0	0.0	0.00	1.00	FES
Forced expiratory volume in 1-second (FEV1), Best measure	4.11	1	1	2.2	0.00	1.00	PSMA4
Mouth/teeth dental problems: Dentures	4.06	1	0	0.0	0.00	1.00	PSMA4
Hayfever, allergic rhinitis or eczema	3.98	2	0	0.0	0.00	1.00	FES SH2B3
Gout (self-reported)	3.89	1	0	0.0	0.00	1.00	SH2B3
Wheeze or whistling in the chest in last year	3.86	2	0	0.0	0.00	1.00	GCHFR PSMA4
Lupus	3.84	1	0	0.0	0.00	1.00	SH2B3
Medication: Lansoprazole	3.82	1	0	0.0	0.00	1.00	SH2B3
Overall health rating	3.81	2	0	0.0	0.00	1.00	GCHFR PSMA4
Headache pain in last month	3.78	1	0	0.0	0.00	1.00	FES
Smoking status: Current	3.65	1	0	0.0	0.00	1.00	FES
Alcohol usually taken with meals	3.64	1	0	0.0	0.00	1.00	FES
Forced expiratory volume in 1-second (FEV1)	3.58	1	1	2.2	0.00	1.00	PSMA4
Knee pain experienced in last month	3.58	1	0	0.0	0.00	1.00	PSMA4
Mouth/teeth dental problems: Mouth ulcers	3.55	1	0	0.0	0.00	1.00	SH2B3
Multivitamins +/- minerals	3.53	1	0	0.0	0.00	1.00	PSMA4
Blood clot in the leg (DVT)	3.49	1	0	0.0	0.00	1.00	SH2B3
Handedness (chirality/laterality): Left-handed	3.44	1	0	0.0	0.00	1.00	FES
Depressed Affect (Nagel 2018)	3.41	1	0	0.0	0.00	1.00	SH2B3
Mood swings	3.37	1	0	0.0	0.00	1.00	SH2B3
Medication: Allopurinol	3.31	1	0	0.0	0.00	1.00	SH2B3
Emphysema/chronic bronchitis	3.27	1	0	0.0	0.00	1.00	PSMA4
Deep venous thrombosis (DVT) (self-reported)	3.24	1	0	0.0	0.00	1.00	SH2B3
Breastfed as a baby	3.21	1	0	0.0	0.00	1.00	FES
Reason for reducing amount of alcohol drunk: Health precaution	3.20	1	0	0.0	0.00	1.00	GCHFR
Bipolar Disorder (2018)	3.12	1	0	0.0	0.00	1.00	FES
Frequency of unenthusiasm / disinterest in last 2 weeks	3.11	1	0	0.0	0.00	1.00	SH2B3
Back pain experienced in last month	3.11	1	0	0.0	0.00	1.00	SH2B3
Lung FVC	3.04	2	1	2.2	0.00	1.00	PSMA4 SH2B3
Chest pain or discomfort	2.96	1	0	0.0	0.00	1.00	GCHFR
Severe depression (siblings)	2.95	1	0	0.0	0.00	1.00	FES
Maternal smoking around birth	2.94	1	0	0.0	0.00	1.00	PSMA4
Vitamin and mineral supplements	2.92	1	0	0.0	0.00	1.00	PSMA4
Diabetes diagnosed by doctor	2.91	1	0	0.0	0.00	1.00	SH2B3
High cholesterol (Self-reported)	2.87	1	0	0.0	0.00	1.00	FES
Type 2 Diabetes (T2D) (2018)	2.80	1	0	0.0	0.00	1.00	SH2B3
Mineral and other dietary supplements	2.79	1	0	0.0	0.00	1.00	FES
Comparative height size at age 10	2.78	2	1	2.2	0.00	1.00	FES SH2B3
Respiratory disease	2.77	1	0	0.0	0.00	1.00	FES
Frequency of tiredness / lethargy in last 2 weeks	2.77	1	0	0.0	0.00	1.00	SH2B3
Body Mass Index (BMI) (2010)	2.75	1	0	0.0	0.00	1.00	SH2B3
Qualifications: NVQ or HND or HNC or equivalent	2.69	1	0	0.0	0.00	1.00	SH2B3
Ovarian Cancer	2.65	1	0	0.0	0.00	1.00	FES
Bilateral oophorectomy (both ovaries removed)	2.56	1	0	0.0	0.00	1.00	PSMA4
Asthma	2.54	1	0	0.0	0.00	1.00	FES
Asthma (self-reported)	2.54	1	0	0.0	0.00	1.00	FES
Irritable Bowel Disease (IBD)	2.48	2	0	0.0	0.00	1.00	FES SH2B3
Age started oral contraceptive pill	2.48	1	0	0.0	0.00	1.00	FES
Arm fat-free mass (left)	2.47	1	1	2.2	0.00	1.00	SH2B3
Arm predicted mass (left)	2.35	1	1	2.2	0.00	1.00	SH2B3
Trunk predicted mass	2.34	2	1	2.2	0.00	1.00	FES SH2B3
Townsend deprivation index at recruitment	2.33	1	0	0.0	0.00	1.00	GCHFR
Trunk fat-free mass	2.33	2	1	2.2	0.00	1.00	FES SH2B3
Crohns Disease (2012)	2.31	1	0	0.0	0.00	1.00	FES
Neck or shoulder pain in last month	2.23	1	0	0.0	0.00	1.00	GCHFR
Neuroticism	2.22	1	0	0.0	0.00	1.00	FES
Illness, injury, bereavement, stress in last 2 years	2.20	1	0	0.0	0.00	1.00	GCHFR
Hair/balding pattern: Pattern 4	2.19	1	0	0.0	0.00	1.00	FES
Forced vital capacity (FVC), Best measure	2.18	1	1	2.2	0.00	1.00	PSMA4
Lung FEV1/FVC ratio	2.17	1	1	2.2	0.00	1.00	PSMA4
Arm predicted mass (right)	2.13	1	1	2.2	0.00	1.00	SH2B3
Whole body water mass	2.12	2	1	2.2	0.00	1.00	FES SH2B3
Supplements: Fish oil (including cod liver oil)	2.12	1	0	0.0	0.00	1.00	FES
Neuroticism (Nagel 2018)	2.10	1	0	0.0	0.00	1.00	FES
Arm fat-free mass (right)	2.09	1	1	2.2	0.00	1.00	SH2B3
Hand grip strength (left)	2.06	1	0	0.0	0.00	1.00	FES
Qualifications: nursing, teaching	2.06	1	0	0.0	0.00	1.00	SH2B3
Whole body fat-free mass	2.05	2	1	2.2	0.00	1.00	FES SH2B3
Crohns Disease (2017)	2.04	1	0	0.0	0.00	1.00	FES
Basal metabolic rate	1.98	2	1	2.2	0.00	1.00	FES SH2B3
Forced vital capacity (FVC)	1.92	1	1	2.2	0.00	1.00	PSMA4
Leg predicted mass (right)	1.82	2	0	0.0	0.00	1.00	FES SH2B3
Impedance of leg (right)	1.80	1	1	2.2	0.00	1.00	FES
Leg fat-free mass (right)	1.79	2	0	0.0	0.00	1.00	FES SH2B3
Impedance of leg (left)	1.75	1	1	2.2	0.00	1.00	FES
Leg fat-free mass (left)	1.66	2	0	0.0	0.00	1.00	FES SH2B3
Leg predicted mass (left)	1.61	2	0	0.0	0.00	1.00	FES SH2B3
Pulse rate	1.61	1	0	0.0	0.00	1.00	SH2B3
Waist Hip Ratio (WHR)	1.55	1	0	0.0	0.00	1.00	GCHFR
Age when periods started (menarche)	1.47	1	0	0.0	0.00	1.00	PSMA4
Hip circumference	1.44	1	0	0.0	0.00	1.00	SH2B3
Peak expiratory flow (PEF)	1.37	1	0	0.0	0.00	1.00	PSMA4
Weight	1.34	1	0	0.0	0.00	1.00	SH2B3
Impedance of arm (left)	1.13	1	0	0.0	0.00	1.00	SH2B3
Standing height	1.02	1	1	2.2	0.00	1.00	SH2B3
Qualifications: College or University degree	1.00	1	0	0.0	0.00	1.00	GCHFR
Height	0.98	2	2	4.4	0.00	1.00	FES SH2B3
Impedance of whole body	0.97	2	0	0.0	0.00	1.00	FES SH2B3
Impedance of arm (right)	0.82	1	0	0.0	0.00	1.00	SH2B3
Sitting height	0.78	1	0	0.0	0.00	1.00	FES
Hair Pigment	0.77	2	2	4.4	0.00	1.00	FES SH2B3
Tanning	0.48	1	0	0.0	0.00	1.00	SH2B3

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adipose Visceral Omentum	0	0.000	1.5
GTEx	Brain Frontal Cortex BA9	0	0.000	1.5
GTEx	Ovary	0	0.000	1.5
The Cancer Genome Atlas	Esophageal Carcinoma	2	0.292	1.5
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	1	0.090	1.5
GTEx	Adipose Subcutaneous	0	0.000	1.4
GTEx	Adrenal Gland	0	0.000	1.4
GTEx	Artery Aorta	0	0.000	1.4
GTEx	Artery Coronary	0	0.000	1.4
GTEx	Artery Tibial	0	0.000	1.4
GTEx	Brain Cerebellum	0	0.000	1.4
GTEx	Brain Cortex	0	0.000	1.4
GTEx	Brain Hippocampus	0	0.000	1.4
GTEx	Brain Hypothalamus	0	0.000	1.4
GTEx	Breast Mammary Tissue	0	0.000	1.4
GTEx	Breast Mammary Tissue (Female)	0	0.000	1.4
GTEx	Colon Sigmoid	0	0.000	1.4
GTEx	Esophagus Gastroesophageal Junction	0	0.000	1.4
GTEx	Esophagus Muscularis	0	0.000	1.4
GTEx	Heart Atrial Appendage	0	0.000	1.4
GTEx	Heart Left Ventricle	0	0.000	1.4
GTEx	Liver	1	0.139	1.4
GTEx	Lung	0	0.000	1.4
GTEx	Muscle Skeletal	0	0.000	1.4
GTEx	Nerve Tibial	0	0.000	1.4
GTEx	Pancreas	0	0.000	1.4
GTEx	Skin Not Sun Exposed Suprapubic	0	0.000	1.4
GTEx	Skin Sun Exposed Lower leg	0	0.000	1.4
GTEx	Small Intestine Terminal Ileum	0	0.000	1.4
GTEx	Stomach	0	0.000	1.4
GTEx	Testis	1	0.032	1.4
GTEx	Thyroid	1	0.025	1.4
GTEx	Uterus	0	0.000	1.4
NTR	Blood	0	0.000	1.4
ROSMAP	Brain Pre-frontal Cortex	0	0.000	1.4
The Cancer Genome Atlas	Glioblastoma Multiforme	1	0.098	1.4
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	0	0.000	1.4
The Cancer Genome Atlas	Skin Cutaneous Melanoma	0	0.000	1.4
The Cancer Genome Atlas	Stomach Adenocarcinoma	1	0.059	1.4
The Cancer Genome Atlas	Testicular Germ Cell Tumors	0	0.000	1.4
GTEx	Brain Caudate basal ganglia	0	0.000	1.3
GTEx	Brain Cerebellar Hemisphere	0	0.000	1.3
GTEx	Brain Nucleus accumbens basal ganglia	0	0.000	1.3
GTEx	Brain Putamen basal ganglia	0	0.000	1.3
GTEx	Breast Mammary Tissue (Male)	0	0.000	1.3
GTEx	Cells EBV-transformed lymphocytes	0	0.000	1.3
GTEx	Cells Transformed fibroblasts	1	0.024	1.3
GTEx	Colon Transverse	0	0.000	1.3
GTEx	Esophagus Mucosa	0	0.000	1.3
GTEx	Pituitary	0	0.000	1.3
GTEx	Prostate	0	0.000	1.3
GTEx	Spleen	0	0.000	1.3
GTEx	Vagina	0	0.000	1.3
GTEx	Whole Blood	0	0.000	1.3
METSIM	Adipose	0	0.000	1.3
YFS	Blood	4	0.087	1.3
CommonMind	Brain Pre-frontal Cortex	0	0.000	1.3
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	0	0.000	1.3
The Cancer Genome Atlas	Breast Invasive Carcinoma	1	0.023	1.3
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	0	0.000	1.3
The Cancer Genome Atlas	Colon Adenocarcinoma	0	0.000	1.3
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	0	0.000	1.3
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	0	0.000	1.3
The Cancer Genome Atlas	Brain Lower Grade Glioma	0	0.000	1.3
The Cancer Genome Atlas	Lung Adenocarcinoma	1	0.034	1.3
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	0	0.000	1.3
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	0	0.000	1.3
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	0	0.000	1.3
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	1	0.075	1.3
The Cancer Genome Atlas	Prostate Adenocarcinoma	1	0.022	1.3
The Cancer Genome Atlas	Rectum Adenocarcinoma	0	0.000	1.3
The Cancer Genome Atlas	Soft Tissue Sarcoma	0	0.000	1.3
The Cancer Genome Atlas	Thyroid Carcinoma	0	0.000	1.3
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.000	1.3